The U.S. Food and Drug Administration approved Nereus (tradipitant), Vanda Pharmaceuticals’ oral neurokinin‑1 receptor agent, marking the first new prescription treatment for motion sickness in more than four decades. The approval was supported by three pivotal studies, including two phase III trials conducted in real‑world maritime settings. Vanda plans a commercial launch in early 2026. Investors reacted quickly: the company’s stock surged on the approval, reflecting both the narrow competitive landscape for motion‑sickness therapeutics and potential near‑term revenue. The clinical program’s emphasis on vomiting prevention in real‑world conditions provided the agency with data aligned to the indication requested. Hospital pharmacies, travel medicine clinics and military procurement groups are immediate commercial targets.